T2 Biosystems Announces Patent Covering In Vivo Application of Direct Detection Technology  
2/28/2013 9:47:02 AM

LEXINGTON, Mass.--(BUSINESS WIRE)--T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced the U.S. Patent and Trademark Office has issued patent 8,368,402 (the ‘402 patent), “NMR systems for in vivo detection of analytes”. This patent covers the use of the Company’s T2MR® technology in an implantable device for the in vivo monitoring of a target analyte. “T2MR technology provides the power to directly detect a target analyte and can be applied to many applications, including detection within the patient’s body,” said John McDonough, President and CEO, T2 Biosystems. “In vivo utilization is a potential application of our core T2MR technology that may ultimately allow patients, especially those with chronic illnesses, to forego routine diagnostic procedures and would provide physicians and patients with rapid, real-time results, enabling more effective treatment decisions.”